J R Masters
Overview
Explore the profile of J R Masters including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
1405
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Masters J
Nat Rev Mol Cell Biol
. 2001 Mar;
1(3):233-6.
PMID: 11252900
Cancer cell lines are used in many biomedical research laboratories. Why, then, are they often described as unrepresentative of the cells from which they were derived? Here, I argue that...
12.
Hudson D, Guy A, Fry P, OHare M, Watt F, Masters J
J Histochem Cytochem
. 2001 Jan;
49(2):271-8.
PMID: 11156695
The prostate grows slowly throughout adult life, leading to benign prostatic hyperplasia (BPH), which often results in urethral obstruction in later years. The symptoms of BPH are the second most...
13.
Hudson D, OHare M, Watt F, Masters J
Lab Invest
. 2000 Aug;
80(8):1243-50.
PMID: 10950115
Clonal analysis of human prostate epithelial cells was undertaken in order to identify stem cells. Two types of colony were distinguished, termed type I and type II. Type I colonies...
14.
15.
Fry P, Hudson D, OHare M, Masters J
BJU Int
. 2000 Feb;
85(4):504-13.
PMID: 10691835
Objective: To use multiple immunofluorescence to compare the in vivo and in vitro expression of tissue-specific proteins in BPH. Materials and methods Pure populations of prostate epithelial and stromal cells...
16.
ONeill C, Koberle B, Masters J, Kelland L
Br J Cancer
. 1999 Dec;
81(8):1294-303.
PMID: 10604725
JM216, an oral platinum drug entering into phase III clinical trial, exhibited comparable cytotoxicity to cisplatin in three human ovarian carcinoma cell lines: the sensitive (CH1), acquired resistant (CH1cisR) and...
17.
Wang X, Fox M, Povey S, Masters J
Somat Cell Mol Genet
. 1999 May;
24(3):165-71.
PMID: 10226654
Testicular germ cell tumors are unusual because they can be cured in over 80% of patients with combination chemotherapy. In order to identify chromosomes carrying genes controlling drug sensitivity, fusions...
18.
Masters J, Popert R, Thompson P, Gibson D, Coptcoat M, Parmar M
J Urol
. 1999 Apr;
161(5):1490-3.
PMID: 10210379
Purpose: We determined the difference in response to high and standard doses of intravesical epirubicin for treatment of superficial bladder cancer. Materials And Methods: A total of 122 patients were...
19.
Bai X, Masters J, ODonoghue N, Kirby R, Pan L, Young M, et al.
Int J Oncol
. 1999 Mar;
14(4):785-91.
PMID: 10087330
The prognostic value of immunohistochemical staining of P53, BCL-2, p27kip1, PSA, AR and MIB-1 was compared with that of established prognostic variables (Gleason score, surgical margins, tumour volume) following radical...
20.
Koberle B, Masters J, Hartley J, Wood R
Curr Biol
. 1999 Mar;
9(5):273-6.
PMID: 10074455
Metastatic cancer in adults usually has a fatal outcome. In contrast, advanced testicular germ cell tumours are cured in over 80% of patients using cisplatin-based combination chemotherapy [1]. An understanding...